{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:37:53Z","timestamp":1792183073967,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Health","award":["1R43CA206668"],"award-info":[{"award-number":["1R43CA206668"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Niclosamide has preclinical activity against a wide range of cancers. In prostate cancer, it inhibits androgen receptor variant 7 and synergizes with abiraterone. The approved niclosamide formulation has poor oral bioavailability. The primary objective of this phase Ib trial was to identify a maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of a novel reformulated orally-bioavailable niclosamide\/PDMX1001 in combination with abiraterone and prednisone in men with castration-resistant prostate cancer (CRPC). Eligible patients had progressing CRPC, adequate end-organ function, and no prior treatment with abiraterone or ketoconazole. Patients were treated with escalating doses of niclosamide\/PDMX1001 and standard doses of abiraterone and prednisone. Peak and trough niclosamide plasma levels were measured. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 and Prostate Cancer Working Group 2 criteria were used to evaluate toxicities and responses. Nine patients with metastatic CRPC were accrued, with no dose-limiting toxicities observed at all dose levels. The recommended Phase II dose of niclosamide\/PDMX1001 was 1200\u00a0mg orally (PO) three times daily plus abiraterone 1000\u00a0mg PO once daily and prednisone 5\u00a0mg PO twice daily. Trough and peak niclosamide concentrations exceeded the therapeutic threshold of\u2009&gt;\u20090.2\u00a0\u00b5M. The combination was well tolerated with most frequent adverse effects of diarrhea. Five out of eight evaluable patients achieved a PSA response; two achieved undetectable PSA and radiographic response. A novel niclosamide\/PDMX1001 reformulation achieved targeted plasma levels when combined with abiraterone and prednisone, and was well tolerated. Further study of niclosamide\/PDMX1001 with this combination is warranted.<\/jats:p>","DOI":"10.1038\/s41598-021-85969-x","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T16:47:41Z","timestamp":1616086061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Phase Ib trial of reformulated niclosamide with abiraterone\/prednisone in men with castration-resistant prostate cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Mamta","family":"Parikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Dall\u2019Era","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Primo N.","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen C.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Xian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"85969_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","volume":"41","author":"W Chen","year":"2018","unstructured":"Chen, W. et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal 41, 89\u201396 (2018).","journal-title":"Cell Signal"},{"issue":"1","key":"85969_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2014.04.003","volume":"349","author":"Y Li","year":"2014","unstructured":"Li, Y. et al. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Lett. 349(1), 8\u201314 (2014).","journal-title":"Cancer Lett."},{"issue":"34","key":"85969_CR3","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1038\/sj.onc.1209598","volume":"25","author":"L Galluzzi","year":"2006","unstructured":"Galluzzi, L. et al. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25(34), 4812\u20134830 (2006).","journal-title":"Oncogene"},{"issue":"12","key":"85969_CR4","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-13-3296","volume":"20","author":"C Liu","year":"2014","unstructured":"Liu, C. et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin. Cancer Res. 20(12), 3198\u20133210 (2014).","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"85969_CR5","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/pros.23015","volume":"75","author":"C Liu","year":"2015","unstructured":"Liu, C. et al. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate 75(13), 1341\u20131353 (2015).","journal-title":"Prostate"},{"issue":"22","key":"85969_CR6","doi-asserted-by":"publisher","first-page":"32210","DOI":"10.18632\/oncotarget.8493","volume":"7","author":"C Liu","year":"2016","unstructured":"Liu, C. et al. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget 7(22), 32210\u201332220 (2016).","journal-title":"Oncotarget"},{"issue":"8","key":"85969_CR7","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1158\/1535-7163.MCT-16-0912","volume":"16","author":"C Liu","year":"2017","unstructured":"Liu, C. et al. Niclosamide and bicalutamide combination treatment overcomes enzalutamide- and bicalutamide-resistant prostate cancer. Mol. Cancer Ther. 16(8), 1521\u20131530 (2017).","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"85969_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0960-0760(97)00049-6","volume":"62","author":"HE MacLean","year":"1997","unstructured":"MacLean, H. E., Warne, G. L. & Zajac, J. D. Localization of functional domains in the androgen receptor. J. Steroid Biochem. Mol. Biol. 62(4), 233\u2013242 (1997).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"15","key":"85969_CR9","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502\u20131512 (2004).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"85969_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411\u2013422 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"85969_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369(3), 213\u2013223 (2013).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"85969_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"Hu, R. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69(1), 16\u201322 (2009).","journal-title":"Cancer Res."},{"issue":"11","key":"85969_CR13","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371(11), 1028\u20131038 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"85969_CR14","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","volume":"35","author":"ES Antonarakis","year":"2017","unstructured":"Antonarakis, E. S. et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J. Clin. Oncol. 35(19), 2149\u20132156 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"85969_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995\u20132005 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"85969_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan, C. J. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 16(2), 152\u2013160 (2015).","journal-title":"Lancet Oncol."},{"issue":"4","key":"85969_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377(4), 352\u2013360 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"85969_CR18","doi-asserted-by":"publisher","first-page":"e0198389","DOI":"10.1371\/journal.pone.0198389","volume":"13","author":"MT Schweizer","year":"2018","unstructured":"Schweizer, M. T. et al. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS ONE 13(6), e0198389 (2018).","journal-title":"PLoS ONE"},{"issue":"1","key":"85969_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12885-018-4197-9","volume":"18","author":"S Burock","year":"2018","unstructured":"Burock, S. et al. Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: The NIKOLO trial. BMC Cancer 18(1), 297 (2018).","journal-title":"BMC Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85969-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85969-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85969-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:40:23Z","timestamp":1670046023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85969-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["85969"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-85969-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"14 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Chengfei Liu, Allen C Gao and Chong-xian Pan are inventors of a patent on niclosamide for the treatment of prostate cancer, which has been licensed by Pandomedx. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6377"}}